Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Exclusive Story Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech SectorReported by Jeffrey Neal Johnson. Posted: 2/24/2026. 
Key Points - Johnson & Johnson has maintained an impressive streak of increasing its dividend payouts for generations, rewarding long-term shareholders with reliable income.
- Management is driving future expansion by focusing on high-growth pharmaceutical assets and cutting-edge medical technologies, such as robotics.
- Investors looking for shelter from market volatility benefit from a stock that historically moves much less than the broader market indices.
- Special Report: [Sponsorship-Ad-6-Format3]
While the technology sector faces a renewed wave of volatility driven by artificial intelligence (AI) scare trades and valuation concerns, a different story is unfolding in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech stocks are finding shelter in a familiar name that is quietly outperforming. Johnson & Johnson (NYSE: JNJ) is trading near all-time highs of approximately $245 per share, creating a divergence that has caught Wall Street's attention. This rally defies the perception of the healthcare giant as a slow-moving, boring stock. Over the last 30 days, shares have climbed roughly 14%, significantly outperforming the broader market during a period of uncertainty. That price action suggests institutional money is rotating out of riskier assets and placing a premium on stability, reliable cash flow, and operational execution. For investors watching the ticker on Feb. 24, 2026, note an important calendar event: today is the ex-dividend date for Johnson & Johnson. The stock price will likely fall by the amount of the upcoming dividend payment — $1.30 per share — a mechanical market adjustment rather than a reflection of business performance. For income-focused investors, that technical dip often represents an attractive entry point rather than a signal to sell. 64 Years of Unbroken Growth The primary case for holding Johnson & Johnson during turbulent market cycles is its financial stability and role as a portfolio stabilizer. The company is part of an elite group known as Dividend Kings, firms that have increased their dividend payout for at least 50 consecutive years. Johnson & Johnson has now raised its dividend for 64 consecutive years, a track record that spans multiple recessions, market crashes, and geopolitical conflicts. That reliability is rare in a market fixated on speculative growth. The stock yields about 2.12%, based on an annual payout of $5.20 per share. While higher yields exist in the bond market or riskier sectors, the appeal here is the combination of growth and safety. Management projects free cash flow of roughly $21 billion in 2026, a level of cash generation that helps ensure the company can continue to pay shareholders, invest in research, and manage legal expenses without heavy borrowing. For risk-averse investors, one of the most compelling metrics is the stock's beta, which measures how much a stock moves compared with the overall market (S&P 500). A beta of 1.0 means a stock moves in lockstep with the market. Johnson & Johnson's beta is about 0.35, meaning it has historically been roughly 65% less volatile than the broader market. When tech stocks swing wildly, J&J tends to hold its ground; adding JNJ to a tech-heavy portfolio acts as a mathematical shock absorber, dampening overall volatility while preserving equity exposure. Beyond the Patent Cliff: The Road to $100 Billion A common misconception about safe stocks is that they cannot grow. Johnson & Johnson is disproving that with a strategic pivot that appears to be working. Management has issued firm guidance for 2026, projecting full-year revenue to cross the $100 billion threshold for the first time in company history. Alongside that milestone, the company anticipates an adjusted earnings per share (EPS) of approximately $11.53. That growth is driven by a reinvention of its pharmaceutical division, now branded as Innovative Medicine. Investors had worried about the patent cliff after Stelara, a blockbuster immunology drug, lost exclusivity in 2025. Instead of a revenue collapse, J&J has offset the decline with the rise of several new blockbusters. Two key assets are driving this resilience: - Darzalex: This oncology powerhouse generates roughly $14 billion in annual sales and has become a foundational therapy in treating multiple myeloma worldwide.
- Tremfya: Positioned as a successor to Stelara, Tremfya recently reported strong three-year remission data for ulcerative colitis, proving the company can retain market share in a competitive immunology space as older drugs fade.
The Tech in MedTech: High-Margin Technologies The growth story extends beyond pharmaceuticals into the MedTech division, which has shifted to focus on high-growth, high-margin technologies. A prime example is the integration of Shockwave Medical, acquired to modernize the cardiovascular portfolio. Shockwave's intravascular lithotripsy (IVL) technology uses sonic pressure waves to safely break up calcified plaque in arteries, similar to how kidney stones are treated. This represents a substantial upgrade over traditional angioplasty balloons. By owning IVL, Johnson & Johnson has secured a high-growth asset that complements its existing heart-pump and surgical businesses. Additionally, the company is advancing in robotics. The submission of its Ottava robotic surgical system for FDA approval signals its intent to compete directly in the rapidly expanding soft-tissue robotics market. These high-tech devices carry higher profit margins and create sticky relationships with hospital systems, providing a long-term earnings tailwind that goes beyond basic consumables. Addition by Subtraction: The Orthopedics Strategy To sustain growth and improve margins, management is reshaping the corporate structure. One major development is the potential separation or sale of the DePuy Synthes orthopedics business. Originally planned as a spin-off, recent reports indicate the company is exploring a mega-sale of the asset. Divesting the orthopedics unit is a classic addition-by-subtraction move. Orthopedics is a mature, lower-growth business compared with booming fields like oncology and advanced cardiovascular technologies. Shedding that slower unit would improve overall revenue growth and profit margins. A sale would also generate a significant lump-sum cash payment, potentially billions of dollars, providing additional capital for acquisitions or share buybacks. Legal risks remain a consideration. The company continues to face litigation over talc products, with a recent $1.5 billion verdict keeping the issue in headlines. A new commercial lawsuit from Bayer over marketing claims for prostate cancer drugs has also added noise. Still, the stock's recent rally suggests the market is looking past these headlines. The prevailing view among bulls is that Johnson & Johnson has the financial depth to manage these liabilities without disrupting operations. With more than $20 billion in cash and marketable securities, the potential proceeds from an orthopedics sale, and about $21 billion in annual free cash flow, the company has a financial cushion that makes legal settlements a balance-sheet item rather than an existential threat to the dividend or core business. Capital Preservation With Upside Johnson & Johnson has evolved from a slow-moving conglomerate into a more focused, high-tech healthcare company. By spinning off its consumer health division (Kenvue (NYSE: KVUE)) and potentially divesting orthopedics, the company is streamlining to concentrate on high-growth opportunities in pharmaceuticals and medical technology. Although the stock is no longer a bargain, trading near all-time highs, it offers a compelling blend of capital preservation and upside. The combination of a 64-year dividend growth streak, a notably low volatility profile, and a clear path to $100 billion in revenue makes J&J an attractive option for 2026. For investors tired of the unpredictability in the technology sector, Johnson & Johnson demonstrates that, in the current market environment, boring can be both beautiful and profitable.
| 
